Followers | 417 |
Posts | 34738 |
Boards Moderated | 1 |
Alias Born | 08/22/2004 |
Tuesday, July 20, 2021 10:32:34 AM
Recent IMNM News
- Immunome Appoints Sandra M. Swain to Board of Directors • Business Wire • 04/25/2024 12:26:00 PM
- Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting • Business Wire • 04/05/2024 12:00:00 PM
- Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets • Business Wire • 03/28/2024 08:02:00 PM
- Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala • Business Wire • 03/26/2024 12:00:00 PM
- Immunome to Participate in the Leerink Partners Global Biopharma Conference • Business Wire • 03/07/2024 01:00:00 PM
- Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference • Business Wire • 03/01/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:10:50 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:07:36 AM
- Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors • Business Wire • 02/20/2024 01:15:00 PM
- Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares • Business Wire • 02/16/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:11:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/14/2024 09:09:03 PM
- Immunome Announces Pricing of Public Offering of Common Stock • Business Wire • 02/14/2024 03:38:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/13/2024 09:36:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:10:43 PM
- Immunome Announces Proposed Public Offering of Common Stock • Business Wire • 02/13/2024 09:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 07:10:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:05:29 PM
- Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • Business Wire • 02/05/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/02/2024 09:04:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 01:53:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 01:50:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 10:27:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:05:49 PM
- Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform • Business Wire • 01/08/2024 12:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM